BIAF bioAffinity Technologies, Inc.: Enterprise Value-to-Revenue Multiple

The price-to-sales trend for bioAffinity Technologies (BIAF) demonstrates a phase of market maturity, with the value holding at 417.72. A stable management team possesses recognized expertise in cancer diagnostics and is successfully expanding the distribution network. Quality management maintains transparent CyPath data, although scaling requires significant investment. Revenue is based on the sale of non-invasive tests for high-risk groups, helping laboratories detect lung tumors at early stages.
bioAffinity Technologies Inc. - analytical breakdowns and key metrics (BIAF)

The investment attractiveness of bioAffinity Technologies (BIAF) depends on the market's ability to adopt its diagnostic tests, making the valuation relative to revenue critically important. This metric correlates the total enterprise value, adjusted for net debt, with annual turnover, allowing the company to assess the premium paid for future growth via the EV/Sales ratio amid slow product adoption and high commercial resistance.